

# SURVEILLANCE STUDY OF PHOTOCOCONTACT DERMATITIS LEADING TO HOSPITALIZATION IN EUROPE WITH A SPECIAL FOCUS ON TOPICAL KETOPROFEN AND OTHER TOPICAL NSAIDs, INCLUDING EVALUATION OF SEVERE PHOTOSENSITIVITY REACTIONS (KETO1)

**First published:** 29/06/2012

**Last updated:** 23/04/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS2679

### Study ID

28279

### DARWIN EU® study

No

## **Study countries**

- Czechia
- France
- Italy

---

## **Study description**

Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic effects. Topical ketoprofen is used in more than 70 countries worldwide. In spite of having been associated with photocontact dermatitis, limited data are available on incidence rate of reactions leading to hospitalization and on risk factor for the reaction. As requested by EMA in 2010 (procedure No. EMEA/H/A-107/1259) and to better evaluate the risk and benefit profile of topical ketoprofen, an epidemiologic case-control study was proposed focusing on severe photosensitivity reactions leading to hospitalization and assessing risks linked to the use of topical ketoprofen and other topical NSAIDs. The study will be conducted on a Europe-wide scale and requires that clear assumptions are made about exposure rates, criteria to define cases of severe photosensitivity, and incidence of severe photosensitivity reactions. To assess the feasibility of such a case-control study before embarking into a Europe-wide large-scale endeavor, a pilot study will be conducted focusing on incidence rates of severe photosensitivity reactions leading to hospitalization, and prevalence of exposure to topical ketoprofen among controls. These pieces of information will be used to estimate the sample size and the statistical power of the case control study. The pilot phase will also address methodological issues granting validity to the study, including standardization of diagnostic criteria and comparison between exposure among controls and exposure in the underlined at risk population so that indirect methods to assess attributable risks could be applied in the case control study. Centers in three geographic areas, intended to represent the variety of Europe in terms of different rates of exposure to topical NSAIDs and of incidence of photosensitivity reactions, will

participate to this pilot study (Lombardy region, Paris metropolitan area, Prague metropolitan area).

## Study status

Finalised

## Research institutions and networks

### Institutions

#### [Centro Studi GISED](#)

Italy

**First published:** 17/04/2012

**Last updated:** 20/08/2024

**Institution**

**Not-for-profit**

#### [UPEC-Université Paris-Est Créteil Val de Marne](#)

Paris, France, 2nd Medical School, Charles

[University Prague, Czech Republic](#)

### Networks

#### [REACT](#)

# Contact details

## **Study institution contact**

Luigi Naldi luigi.naldi@gised.it

**Study contact**

[luigi.naldi@gised.it](mailto:luigi.naldi@gised.it)

## **Primary lead investigator**

Luigi Naldi

**Primary lead investigator**

# Study timelines

## **Date when funding contract was signed**

Actual: 24/04/2012

---

## **Study start date**

Planned: 01/09/2012

Actual: 02/10/2012

---

## **Data analysis start date**

Planned: 15/11/2012

Actual: 15/11/2012

---

## **Date of interim report, if expected**

Planned: 01/12/2012

Actual: 06/12/2012

---

## **Date of final study report**

Planned: 30/04/2013

Actual: 05/11/2013

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Menarini, Bayer SpA, Cyathus, Dompè SpA, EG SpA, JSC Grindeks, Hisamitsu Ltd, Istituto Biochimico Italiano, Italfarmaco SpA, Pierre Fabre, Sanofi-Aventis, Sandoz

## Study protocol

[Ketoprofen\\_-\\_Pilot\\_phase\\_Protocol\\_F.1\\_11-06-2012\[1\].pdf](#) (333.67 KB)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 3 (required)

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Disease /health condition

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Drug utilisation

**Data collection methods:**

Primary data collection

---

**Main study objective:**

-to assess the prevalence of exposure to topical NSAIDs in a sample of hospital controls selected as in case-control studies-to develop strict diagnostic criteria for severe photosensitivity-to estimate the incidence of severe photosensitivity leading to hospitalization in selected sampling areas.

## Study Design

**Non-interventional study design**

Case-control

## Study drug and medical condition

**Anatomical Therapeutic Chemical (ATC) code**

(M01A) ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

(M01AE03) ketoprofen

ketoprofen

---

### **Medical condition to be studied**

Photosensitivity reaction

## Population studied

### **Short description of the study population**

Patients with following criteria were included:

1. Age 18-74 years
2. Consecutive patients of both gender admitted for any of the following acute conditions or elective procedures:
  - Acute infection or inflammation\*: pneumonia, gastroenteritis, cellulitis, pancreatitis (first episode), otitis media, peritonitis, epididymitis, abscess, meningitis, encephalitis, pelvic inflammatory disease
  - Trauma (not related to alcohol or osteoporosis): fractures, sprains/strains, dislocations
  - Acute abdominal emergencies\*: appendicitis, strangulated hernia, rupture or torsion of an ovarian cyst, acute abdominal pain, ectopic pregnancy, thrombophlebitis (males only, first episode)
  - Spontaneous pneumothorax
  - Alternative diagnoses (when the previous ones are not available): hernias, hallux valgus, cosmetic surgery, deviated nasal septum

\* Diagnosis in this group are not all-inclusive, but rather examples of appropriate conditions

- Signed informed consent

---

## **Age groups**

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)

---

## **Estimated number of subjects**

900

# **Study design details**

## **Outcomes**

-the estimate of prevalence of exposure to topical ketoprofen in the general population. A secondary outcome will be the prevalence of exposure to other topical NSAIDs -The definition of a standard operative procedure for the identification and diagnosis of photosensitivity reactions-The estimate of the incidence of photosensitivity reactions in selected European areas

---

## **Data analysis plan**

Row and age-standardized prevalence rates together with their 95% confidence intervals (CI) will be calculated for NSAIDs exposure as well as for other variables of interest. Stratification by gender and country will be used for general descriptive statistics as well as for exposure rates. Differences among categories will be tested with Pearson's chi-squared test or Fisher's exact test for nominal variables and by Mann-Whitney U test for continuous variables. To estimate possible selection biases in the collection of the sample, a comparison of general characteristics of individuals undergoing the interview and, in particular, their exposure rates to topical NSAIDs, with the expected distribution based on demographic and general sales data obtained from individual areas will be made. Whenever it will be possible risk estimate for exposure will be

derived from odds ratio calculation. Multiple logistic regressions will be used to adjust risk estimates for potential confounders.

## Documents

### **Study, other information**

[Keto1\\_vers F1 Questionnaire 11-06-2012.pdf \(457.2 KB\)](#)

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### **Composition of steering group and observers**

[Composition of the Steering Committee.pdf \(108.05 KB\)](#)

## Data sources

### **Data sources (types)**

Other

### **Data sources (types), other**

Prospective patient-based data collection

## Use of a Common Data Model (CDM)

## **CDM mapping**

No

# Data quality specifications

## **Check conformance**

Unknown

---

## **Check completeness**

Unknown

---

## **Check stability**

Unknown

---

## **Check logical consistency**

Unknown

---

# Data characterisation

## **Data characterisation conducted**

No